Interesting- who responds to PD1- to be followed up

Observation to be followed up systematically-

Response to PD1 antibody seems to depend on T-cells being present in the tumour, with patients with more T-cells responding better than the ones without.

Interesting, with CTL4 and PD1, it doesn't seem to matter as CTL4 drives T-cells into the tumour



Yesterday, A. Ribas suggested in a session a future model where treatment choices are based on the amount of T-cells present in the tumor-

patients with a lot of T-cells could just get PD1 - and less toxicity.